Research describes a context
Materials sold for research have not thereby become authorised consumer medicines. A seller using scientific vocabulary or a research-use statement does not establish that a product is appropriate for personal treatment.
Approval is product-specific
When evaluating a medicine, verify the exact approved product, indication and current official information with the relevant regulator. Do not extend an approval for one product or route to another substance or unreviewed formulation.
Compounding is a different framework
FDA explains that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before marketing. Compounding and routine product approval are distinct regulatory contexts. Patients should discuss legitimate treatment needs with qualified clinicians.
How PeptideC handles this category
Medical and research selections in the discovery tool lead only to education and primary sources. There are no personalised treatment matches, injection calculations or consumer checkout links for unapproved medical peptides.
Sources & references
- FDA: Understanding the Risks of Compounded Drugs ↗
- FDA: Bulk drug substances that may present significant safety risks ↗
- FDA: Is It a Cosmetic, a Drug, or Both? ↗
A chemical record identifies a reference, a study reports a defined investigation, and a product label concerns a specific medicine. A supplier catalogue is not clinical evidence.
General education, not personal medical advice. Ask an appropriately qualified professional about a medicine, symptom or treatment question.